BioXcel Gets Nod For $125M Bankruptcy Sale To Teva
A Delaware bankruptcy judge Wednesday gave the OK to artificial intelligence-powered pharmaceutical group BioXcel to proceed with a $125 million sale to Israeli drugmaker Teva Pharmaceuticals, and allowed the debtor to...To view the full article, register now.
Already a subscriber? Click here to view full article